BioNTech SE
@BioNTech_Group
Followers
81K
Following
44
Media
199
Statuses
290
Our vision: Harnessing the immune system’s power to turn science into survival. Data Privacy: https://t.co/ZHMXceTxRG Imprint: https://t.co/VNRPNHg7b0
Mainz, Germany
Joined November 2018
🔗 Highlights of our oncology programs to be presented at ASCO:
investors.biontech.de
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology...
0
1
6
At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies. 🗓 May 30 – June 3 | Chicago .📍 Booth #35165. #CancerResearch #ImmunoOncology #OncologyInnovation
1
7
36
🔗 Read more about our Q1 updates (including our forward-looking statements):
investors.biontech.de
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and...
0
1
3
We aim to tackle one of the most lethal cancers worldwide: #LungCancer. This week, we are joining the global community at the #ELCC25 presenting new data for our PD-L1/VEGF-A bispecific antibody candidate in metastatic #SCLC. 👉Learn more about the data:
0
6
46
👉Link to PR and forward-looking statements disclaimer:
investors.biontech.de
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers With the closing of the...
0
0
5
🚀 Update: We completed the acquisition of Biotheus. This strengthens our capabilities to develop, manufacture and commercialize next-gen bispecific antibodies, including BNT327 (PD-L1xVEGF-A bispecific), and supports the global execution of our oncology strategy.
1
11
63
📊 Interim Ph1b/2 data for anti-PD-L1/VEGF-A bispecific antibody candidate BNT327 show a 73.8% cORR and a manageable safety profile (primary endpoints) with a mature 18-month OS rate of 69.7% (secondary endpoint) in 1L TNBC at #SABCS24. 👉 Find out more:
1
3
13
We are excited to be attending this year’s #SABCS24, with new interim Phase 1b/2 data for our anti-PD-L1/VEGF-A bispecific antibody candidate BNT327/PM8002 in triple-negative #BreastCancer (#TNBC). 📍Visit us at booth # 226 to explore the latest data for this asset.
1
8
45
Advancing our oncology strategy: by strengthening next-gen immuno-modulator capabilities, we’re enhancing one core pillar of our oncology strategy.With investigational assets like BNT327/PM8002,our pipeline aims to build a new backbone in immuno-oncology.
24
10
36
The @US_FDA granted Fast Track designation for our #ADC candidate BNT324/DB-1311 for the treatment of castration-resistant #ProstateCancer. With this, all 3 clinical ADC candidates in our collab with #DualityBio have received Fast Track designation.
7
14
81
📊 Clinical trial data presentation for programs from our immuno-oncology pipeline & real-world data from 2 observational trials. 👉Explore our updates:
0
2
16
